Health News (Reuters)

Philippines fines Sanofi, suspends clearance for Dengvaxia

MANILA (Reuters) - The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, its health secretary said on Thursday.

Air pollution around conception tied to birth defects

(Reuters Health) - - Women who breathe polluted air during the month right before or after they get pregnant may be more likely to have babies with birth defects, a U.S. recent study suggests.

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

(Reuters) - Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Click bait ads are tied to teen smoking

(Reuters Health) - - Teens who engage with online tobacco ads are more likely to start smoking than their peers who aren’t lured by digital marketing campaigns, a U.S. study suggests.

FDA issues recall on J&J heart device

(Reuters) - The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve, following a recall by the company in June.

Immune boosting virus could be used to treat brain tumors

LONDON (Reuters) - A trial of a potential new brain cancer treatment has shown that a virus injected directly into the bloodstream can reach tumors deep inside the brain and switch on the body's own defense system to attack them.

How alcohol damages stem cell DNA and increases cancer risk

LONDON (Reuters) - Drinking alcohol produces a harmful chemical in the body which can lead to permanent genetic damage in the DNA of stem cells, increasing the risk of cancer developing, according to research published on Wednesday.

Spark to charge $850,000 per patient for blindness gene therapy

(Reuters) - Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

Majority of French now favor allowing surrogate motherhood: poll

PARIS (Reuters) - A majority of French people would favor allowing surrogate motherhood, though primarily only for medical reasons, a poll showed on Wednesday, highlighting a shift in attitudes as France prepares to review laws relating to assisted reproduction.

Drugmakers raise 2018 U.S. prices, stick to self-imposed limits

NEW YORK (Reuters) - Drugmakers opened the new year by raising U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit in response to a backlash from consumers and politicians.

Atrial fibrillation more deadly in rural U.S. hospitals

(Reuters Health) - - Among U.S. patients hospitalized for the common heart rhythm disorder known as atrial fibrillation, those in rural areas may be more likely to die than their urban counterparts, a new study suggests.

Race may matter in hospital care for preemies

(Reuters Health) - Among the tiniest preemies, black and Hispanic infants are more likely than white babies to be born at hospitals with worse death and complication rates, a study in New York City suggests.

FDA issues recall on J&J heart device

(Reuters) - The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve.

Pages